Navigation Links
Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
Date:10/16/2007

Up to One Quarter of Managed Care Organizations Fail to Cover Agents with Proven Benefit for Cancer Patients, According to a New Report from Decision

Resources

WALTHAM, Mass., Oct. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists want to see significant improvement in overall survival before adopting targeted polypharmacy in first-line settings. According to the new Physician & Payer Forum report entitled Premium-Priced Targeted Agents in Oncology: Clinician and Payer Attitudes to Polypharmacy, surveyed oncologists were asked what the minimum benefit is that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of advanced non-small-cell lung cancer (NSCLC).

In this first-line treatment scenario, the largest group of oncologists (41 percent) would require a significant improvement in overall survival in order to add Erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent improvement in median survival, which would represent close to three months' additional survival, a very difficult requirement to meet in advanced NSCLC. Only 37 percent of oncologists expect Erbitux/Avastin to increase median survival of NSCLC patients.

The report also finds that up to one quarter of managed care organizations (MCOs) fail to cover both agents where two similar targeted agents are available. Marketers of Tykerb, Nexavar, Sutent, and Sprycel need to address the fact that some MCOs appear to perceive Herceptin/Tykerb, Nexavar/Sutent, and Gleevec/Sprycel as interchangeable, "me too" agents.

"Evidence demonstrates that patients who have failed Herceptin in the metastatic setting should switch to Tykerb, patients who have failed Gleevec should switch to Sprycel, and, according to National Cancer Instit
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Emerging technology companies receive significant funding
2. Genzyme acquistion of Bone Care approved, significant impact forecast
3. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
4. Manufacturing group says efforts led to big improvements
5. Part 6 Project Performance Get on the path to continuous improvement
6. Part 5 Project Performance Get on the path to continuous improvement
7. Part 4 Project Performance Get on the path to continuous improvement
8. Part 3 Project performance Get on the path to continuous improvement
9. Part 2 Project performance Get on the path to continuous improvement
10. Part 1 Project performance Get on the path to continuous improvement
11. Finding a Yardstick For Local Biotech Improvement and Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources Group ... medical directors in the United States ... biosimilar market penetration will be the level of ... and the expected lower cost to patients. Payers ... that meet their pricing expectations in order to ...
(Date:7/30/2014)... July 30, 2014  The Chicago Bears are excited ... of Dermatology (Academy) in an effort to raise awareness ... will host free SPOT me™ skin cancer screenings at ... Soldier Field. SPOT me™ is an educational campaign ... dangers and risks of skin cancer, and encourages people ...
(Date:7/30/2014)... While administrative claims and other ... for a relatively long period of time, there ... use of these ‘big data’ for comparisons of ... today’s powerful computer technology with the plethora of ... holds significant promise for identifying optimal interventions for ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Immunodiagnostics Markets: US, Europe, Japan Product ... for Instrumentand Reagent Suppliers ...
... 25, 2011 Practice Fusion , the ... working with Microsoft,s DataMarket on the Windows Azure Marketplace ... developers and researchers is part of the Health 2.0 ... Developer Challenge with the support of the Chief Technology ...
... Jan. 25, 2011 Reportlinker.com announces that ... in its catalogue: Future ... of Emerging Reimbursement, Technological and Market Trends ... How will the ...
Cached Biology Technology:Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers 2Practice Fusion Invites Health Researchers to 'Analyze This!' Contest on Windows Azure 2Practice Fusion Invites Health Researchers to 'Analyze This!' Contest on Windows Azure 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2
(Date:7/30/2014)... infection could be as simple as inserting a medicated, ... of Washington bioengineers have discovered a potentially faster way ... contracting HIV. Their method spins the drug into silk-like ... releasing higher doses of the drug than possible with ... "This could offer women a potentially more effective, discreet ...
(Date:7/30/2014)... climate threaten some of the world,s most rare ... seed collections to save the seeds in banks ... genetic diversity., For decades, these seed collections have ... one-size-fits-all approach for how many seeds to gather, ... of species, pollination mode, growth habitat and population ...
(Date:7/30/2014)... Americans make better decisions about what they eat, the ... significant changes to the Nutrition Facts label found on ... in Chemical & Engineering News (C&EN), the ... the suggested updates and the fight that has ... points out that while the Nutrition Facts label has ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3Saving seeds the right way can save the world's plants 2
... have charted the path of insulin action in cells in ... for understanding what goes wrong in diabetes. The ... from Sydney,s Garvan Institute of Medical Research, is now published ... Cell Metabolism . First discovered in 1921, the insulin ...
... (MAY 20, 2013) University of Minnesota Medical School ... in partnership with the University,s Brain Tumor Program, have ... sheath tumors (MPNST) that allow them to discover new ... The research was published this week in the ...
... A National Science Foundation (NSF) planning grant will help ... a joint program of the University of Illinois at ... "CARD will be devoted to research in drying ... products; forestry and paper products; chemical products; textiles; and ...
Cached Biology News:Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: